David Hyman, MD | Authors

Articles

Efficacy Results for LOXO-101 in TRK Fusion Cancers

June 03, 2017

Video

David Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

A Phase I Study of the Angiopoietin-2 Inhibitor MEDI3617

August 15, 2014

Video

David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I study of MEDI3617 for advanced solid tumors.